REDWOOD CITY, CA / ACCESSWIRE / September 17, 2019 / Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced today announced that Jeff Soinski, CEO, will present at the Ladenburg Thalmann Healthcare Conference on Tuesday, September 24, 2019, at 2:00 pm Eastern Time, at the Sofitel Hotel in New York City. The presentation will be webcast, both live and in an archived format, with a link available at www.avinger.com under “Investors,” then “Events & Presentations.”
Management will be available to meet with investors throughout the day on Tuesday, September 24. Investors wishing to schedule a meeting should contact Ladenburg Thalmann or Avinger Investor Relations at mkreps@darrowir.com.
About Avinger, Inc.
Avinger is a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD). PAD is estimated to affect over 12 million people in the U.S. and over 200 million worldwide. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot family of chronic total occlusion (CTO) catheters, and the Pantheris® family of atherectomy devices. Avinger is based in Redwood City, California. For more information, please visit www.avinger.com.
Investor Contact:
Mark Weinswig
Chief Financial Officer
Avinger, Inc.
(650) 241-7916
ir@avinger.com
Matt Kreps
Darrow Associates Investor Relations
(214) 597-8200
mkreps@darrowir.com
SOURCE: Avinger, Inc.
View source version on accesswire.com:
https://www.accesswire.com/559817/Avinger-to-Present-at-Ladenburg-Thalmann-Healthcare-Conference-on-September-24
Research highlights how nutrition tracking drives success for weight loss and health goals NEW YORK,…
Coeptis Aims to Bring AI Innovation in Biotechnology and Technology WEXFORD, Pa., Dec. 26, 2024…
Slovenia, Croatia, Turkey, and Greece Drive EHR Adoption in the Balkans, Setting New Standards in…
Richland, WA, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to…
– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing…
YARDLEY, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Optinose, Inc. (NASDAQ: OPTN), a pharmaceutical company…